An unprecedented growth of nanotechnology, nanomaterials (sized 1-100 nm) and their medical applications over the past 10 years has promised to add a new impetus to diagnostics and therapeutics of a wide range of human pathologies including cancer, cardiovascular diseases, and diseases of the central nervous system. The growth of nanomedicine fuels also advances in bioengineering, regenerative medicine and medical devices development. However, as with all new pharmaceuticals and medical devices new opportunities are inherently accompanied by new challenges due to the ability of nanomaterials to interact with the body at cellular, subcellular and molecular levels. This article reviews some of the most compelling problems related to nanopharmacology and nanotoxicology of nanomaterials. In our overview, we will focus on opportunities brought about by the development of multifunctional nanomaterials and nanotheranostics for diagnostics and therapeutics of major and rare diseases. We will also discuss challenges related to haemocompatibility of nanomaterials.
Introduction
The 2011 European Commission recommendation defines "nanomaterial" as "a natural, incidental or manufactured material containing particles, in an unbound state or as an aggregate or as an agglomerate and where, for 50 % or more of the particles in the number size distribution, one or more external dimensions is in the size range 1 nm-100 nm. In specific cases and where warranted by concerns for the environment, health, safety or competitiveness the number size distribution threshold of 50 % may be replaced by a threshold between 1 and 50 %.
[…]" [1] .
The world market size for nanomaterials has been growing extremely fast. It is estimated that 11 million tonnes of nanomaterials are annually produced with the market value of 20 bln € and products underpinned by nanotechnology are valued in 2015 at 2 trn € [1] .
It is important to note that nanotechnology is viewed by the European Union (EU) as one of the major technological drivers of innovation and has been identified as the key enabling technology (KET) for the EU [2] .
Medicine is expected to be one of the major beneficiaries of nanotechnology growth. This is reflected by a great interest of scientific community in medical applications of nanotechnology. At the time when this article was written (October 2015) the search for "nanomedicine" and "nanoparticles" in Pubmed listed 11,114 and 109,996 publications, respectively. A significant part of these contributions have been published in newer journals entirely focusing on nanotechnology and nanomedicine including Nature Nanotechology, Nanomedicine (Lond.), Nanomedicine NBM or International Journal of Nanomedicine to name only a few.
In 2007 in a highly-accessed and -cited article published in British Journal of Pharmacology [3] we have alerted pharmaceutical community to a new and growing field of nanotechnology research relevant to pharmacology and toxicology. Over the past 8 years the field has grown very rapidly resulting in publication of a great number of original and review articles. Table 1 presents selected published reviews covering a cross section of nanomedicine, nanopharmacology and nanotoxicology topics.
As with all medical Research and Development (R&D), in nanomedicine diagnostic and therapeutic options, in addition to new opportunities, bear certain risk and the risk/benefit balance is likely to influence the fate of nanomedical R&D.
In this overview, we will focus on opportunities brought about by the development of multifunctional nanomaterials for diagnostics and therapeutics. We will also discuss challenges related to biocompatibility of newly developed nanomaterials highlighting blood-nanoparticle interactions.
Opportunities
Most of nanodrug research to date has been based on the principle of using nanoparticles as drug delivery platforms. In fact, the first nanodrug approved by the Food and Drug Administration (FDA) for use in men was Doxil [4] where liposomal encapsulation of doxorubicin was used to increase the drug/carrier ratio and decrease cardiac toxicity and adverse effects associated with the use of this anticancer drug [5] .
Up to date >40 nanopharmaceuticals have been approved by the regulatory authorities including liposomes, non-liposomal lipid formulations, PEGylated proteins, peptides, aptamers, nanocrystals, polymer-based nanoformulations, protein-drug conjugates, surfactant-based nanoformulations, metal-based nanoformulations and virosomes [6] .
The field of anticancer drug delivery has been a major beneficiary of nanomedical R&D with a number of FDA-approved anticancer formulations such as nanosized antibody-drug conjugates: brentuximab and trastuzumab [7] , liposome-containing daunorubicine [8] and vincristine [9] , as well as paclitaxel formulated using nanosized albumin carrier [10] . As with Doxil the use of nanoplatforms is likely to increase the selectivity and efficacy and reduce the adverse effects of these anticancer drugs.
A number of nanotherapeutic products are commercially available in the EU including nanocrystals (sirolimus, fenofibrate and aprepitant), nanoemulsions (cyclosporine and ritonavir) polymeric drugs (sevelamer) or liposomes (amphotericin B, cytarabine, doxorubicin and daunorubicin) [11] .
Recently, yet another dimension of nanoparticle drug delivery system has been gaining increasing momentum in the nanomedical R&D. This is nanotheranostics based on the use of multifunctional nanoparticles that integrate diagnostic and therapeutic functions in one system [12] . For cancer treatment nanotheranostics platforms comprise advanced diagnostics, hyperthermia treatment and targeted delivery of anticancer drugs [13] . Ferromagnetic iron oxide nanoparticles (SPION) are an example of such platforms [14, 15] . They have been also developed as a part of our MULTIFUN EU consortium (http://www.multifun-project.eu/) [16] and offer distinct advantages over other drug delivery platforms used to deliver anticancer medications: a) the pharmacokinetics of SPION is easily determined using non-invasive imaging techniques such as NMR, b) SPION can be easily guided to cancer tissues using electromagnetic field (EM), c) SPION can selectively generate energy to destroy cancer cells and d) SPION when functionalized with antibodies against cancer biomarkers can selectively deliver a "cocktail" of therapeutic pharmaceuticals (Figure 1a ). Nanotheranostics can be also used for the management of atherosclerosis and its cardiovascular and cerebrovascular manifestations [17] [18] [19] . As with cancer it is expected that multimodal nanoparticles will allow for non-invasive detection, long-term monitoring (for example using gadolinium-based contrasts and dynamic contrast enhanced magnetic resonance imaging) and treatment of atherosclerotic plaques [20, 21] . The European Union actively supports projects related to the use of nanomedicine to combat atherosclerosis. One of the ongoing projects is NanoAthero consortium (http://www.nanoathero.eu/) that aims at targeted imaging and treatment of advanced atherothrombotic disease in humans.
In addition to major diseases such as cancer and cardiovascular diseases, nanotheranostics may also be applied to the diagnostics and treatment of rare diseases. Kasabach -Merrit syndrome [22] also known as Kasabach -Merrit Phenomenon (KMP) or thrombocytopenia with a vascular lesion is a rare condition (National Organization for Rare Disorders, NORD, http://rarediseases.org/) that complicates the course of two rare vascular tumours kaposiform haemangioendothelioma (KHE) and tufted angioma (approximately 1% of all haemangioma) believed to be a spectrum of the same disease [23]. Albeit a rare disease, KMP is a life threatening one leading to profound thrombocytopenia (3,000-60,000/µL) hypofibrinogenaemia, bleeding and sometimes to disseminated intravascular coagulation. The exact pathogenesis of KMP is uncertain; however, trapping of platelets in haemangioma with abnormal proliferating endothelium is the most likely cause [24] . Despite various treatment modalities including surgery, supportive and systemic pharmacological treatment the prognosis of KMP remains uncertain [25] and, therefore, there is an urgent need to develop more effective treatments. The use of multifunctional ferromagnetic nanoparticles may represent such a theranostic option (Figure 1 
b).

Challenges
Nanomaterials can enter the body via a number of portals such as skin, respiratory tract, and gastrointestinal tract or through parenteral administration [26, 27] . Translocation of nanoparticles to the bloodstream allows for interactions between nanomaterials plasma and blood elements to take place. The contact of nanoparticles with plasma proteins leads to formation of "protein corona" [28] , which may modify the biological and pharmacological properties of nanoparticles [29] .
Over the past 10 years our group has pioneered and studied the effects of nanoparticles on vascular haemostasis and blood platelet function as platelet-nanoparticle interactions are likely to play a major role in haemocompatibility of nanomaterials. We have shown that soluble and surface-bound carbon nanoparticles have the ability to stimulate platelet aggregation and increase thrombosis in vitro and in vivo [30, 31] The understanding of subcellular mechanisms involved in nanomaterial haemocompatibility, as well as the availability of sensitive methods for studying such interactions will be of great assistance when developing diagnostic and therapeutic options using multifunctional nanomaterials. Multifunctional nanoparticles including materials with ferromagnetic core rely on their ability to interact efficiently with EM fields to produce a response via scattering or absorption of the interacting field [42] . The EM-mediated responses may be used for selective detecting, targeting, monitoring and treating a wide cross section of human diseases. However, the impact of EM field on interactions between mutlifunctional nanoparticles, cells and subcellular structures needs to be carefully evaluated to compile the risk/benefit ratio of such pharmaceuticals.
It is also important to point out that despite the commonality of nanosize there are compelling differences between various medically relevant nanomaterials. Therefore, the R&D as well as registration of novel nanodiagnostic/nanotherapeutic agents with FDA and EU is likely to proceed on the case-to-case basis. The pharmaceutical industry may, however, be vitally interested in nanotherapeutic ventures. Indeed, over the past few years large, research-intensive pharmaceutical companies have had to deal with the effects of so-called "patent-cliff". The patent-cliff results from expiry of patents for major pharmaceutical blockbusters, which leads to decreased pharma sales. Therefore, uniquely formulated nanodrugs based on the existing compounds may be one way to go for the research-intensive pharma industry to deal with patenting problems [43] .
Finally, it is worth to comment on the risk and safety assessment associated with the use of nanopharmaceuticals. As indicated in the Opportunities section, both FDA and EU have already set up robust schemes for approval and legislation of new nanopharmaceuticals and these schemes appear to be working well and provide the comprehensive pharmacological/toxicological profile of novel nanopharmaceuticals. The challenge that requires a very careful consideration is the environmental presence and persistence of engineered nanoparticles. It is likely that organic, biodegradable nanoparticles will be of lesser concern as they will be degraded by metabolic pathways [26] . In contrast, inorganic, non-biodegradable nanoparticles, including multifunctional magnetic nanoparticles, may persist long enough and result in prolonged exposure of humans, animals and the environment with still to be determined consequences of such exposure. This, potentially, could add to the pool of engineered nanomaterials present in environment that is continually enriched with nanoproducts produced by food, agriculture and cosmetics industries [26, [44] [45] [46] . The outcome of biological interactions between nanomaterials and xenobiotics present in the environment may also be of concern [47, 48] . Therefore, beyond any reasonable doubt the assessment of environmental risks associated with growing presence of nanotechnology products in the environment needs to be carefully considered [49-51]. A) A general design and functionalization of multifunctional magnetic nanoparticles: magnetic core capable of scattering or absorption of the interacting electromagnetic field allowing for diagnostics and treatment; pharmaceutical load for selective delivery of therapeutics; targeting using antibodies against specific cellular markers and biocompatibility with polyethylene glycol (PEG) allowing for longer half-life of nanoparticles in the bloodstream [13, 42, 53] .
B)
A proposed design of multifunctional ferromagnetic nanoparticles for the treatment of Kasabach-Merrit disease: ferromagnetic core using ferric oxide; pharmaceutical load with a chemotherapeutic agent [24] , NO-barbiturate a strong inhibitor of cancer cell proliferation and secretion [141] and iloprost, an analogue of prostacyclin, a potent inhibitor of platelet aggregation that synergizes with NO [142] ; targeting haemangioma cells using antibodies against vascular endothelial growth factor receptors [143] and EM field; and biocompatibility coat with PEG.
